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Key Points 
 
1. The aetiology of cholesteatoma remains elusive. In a recent systematic review, we 
discussed reports of multiple cases of  cholesteatoma within families, which suggests a 
genetic predisposition in some cases (1).  
2. We have established a U.K. database and DNA sample bank that can be used to identify 
genetic variants that co-segregate with cholesteatoma in multiply-affected families. 
Recruitment to this Genetics of Cholesteatoma (GOC) Study is via the U.K. National 
Institute of Health Research Clinical Research Network.  
3. This preliminary communication describes the results of whole exome sequencing (WES) 
of DNA extracted from participants in the first fully sequenced family recruited to the 
study.  
4. Rare variants were filtered for co-segregation with the cholesteatoma phenotype, and for 
their putative functional impact.   
5. We have identified loss of function variants in the genes EGFL8 and BTNL9 as candidate 
variants of interest. These are preliminary observations and the variants are of unknown 
significance to the disease pathology without replication or further investigation. 
 
Introduction 
 
The aetiology of cholesteatoma is uncertain. Abnormality of drum skin migration and 
desquamation is thought to predispose to the accumulation of cholesteatoma within the 
middle ear, which may be locally invasive and capable of causing bone destruction and 
associated inflammation (2, 3).  Reports of familial clustering of disease suggest genetic 
predisposition, but to date no genetic susceptibility loci have been identified (1).  
The lead author (PP) previously reported the largest series of families affected by 
cholesteatoma (4).  One of the families reported in that study participated in the present 
study to investigate susceptibility loci.  This family has several affected members (figure 1), 
and we were able to obtain DNA from five members, enabling whole exome sequencing 
(WES) and analysis of variants to identify those segregating with disease.  The affected 
identical twin girls presented with glue ear at 5 years of age and were treated with bilateral 
grommets. At 7 years of age, they represented with otorrhoea and hearing loss. A clinical 
diagnosis of cholesteatoma was made. In the unilateral case in one of the twins, an extensive 
cholesteatoma was revealed with disease filling the middle ear and extending towards the 
petrous apex with erosion of the horizontal facial nerve canal. In the other twin, more limited 
disease was revealed in the left ear with cholesteatoma in the anterior middle ear and 
antrum. In the right ear, the disease was limited to the attic region. Tympanomastoidectomy 
was performed resulting in small dry cavities and hearing preservation, as had been the case 
with the older brother. CT scans were not performed. 
Sequencing the exome of affected and unaffected individuals in families affected by 
cholesteatoma has the potential to identify variants in coding DNA that co-segregate with the 
phenotype. This is a preliminary report describing the first use of a whole exome sequencing 
(WES) strategy to study the genetics of cholesteatoma in a family with three affected siblings 
and a wider family history of cholesteatoma and severe ear disease. 
 
Methods 
 
Ethics and Research Governance  
The GOC study was granted ethical approval by East of England Cambridge Research Ethics 
Committee (reference REC 16/EE/01311, IRAS ID: 186786).  The study is sponsored by the 
University of East Anglia. 
Biological samples and DNA extraction 
Blood samples from the five family members indicated in figure 1 were collected in 3ml EDTA 
tubes by the research nurse and DNA extraction was completed using the Gentra Puregene 
Blood Kit (Qiagen, UK). All DNA samples were quantitated, checked for purity, and 
subsequently stored in the sample bank.  
Whole Exome Sequencing (WES): library preparation, target capture and sequencing method  
The whole-exome capture and library construction was performed using an amended v5.1 
protocol from NimbleGen (NimbleGen 2015). The Illumina HiSeq4000 platform was used to 
generate paired-end 150bp reads from the libraries. Next-generation sequencing, library 
construction and primary bioinformatics analysis was delivered by the BBSRC National 
Capability in Genomics (BB/J010375/1) at Earlham Institute by members of the Genomics 
Pipelines Group. 
Bioinformatics and variant filtering 
Sequencing reads were aligned to the GRCh37 (hg19) version of the human genome reference 
sequence, using the Bowtie 2 read aligner. Variants were called with FreeBayes (a Bayesian 
genetic variant detector) and variant call format (VCF) files were produced for each WES 
sample (5). VCFtools were used to intersect the genotype files to identify shared variants. 
Variants were annotated with functional information from Ensembl’s Variant Effect Predictor 
(VEP) (6). 
Variants that segregated with cholesteatoma in the siblings and in the mother were stratified 
to generate a list of candidate variants. For this preliminary analysis of the case series, we 
have considered a dominant model with incomplete penetrance. That is, we filtered for 
heterozygous variants in the affected individuals (and in the mother, because phenotypes of 
interest were recorded for her paternal uncle and for her nephew), and removed variants 
that are heterozygous or homozygous for an alternative (non-reference sequence) allele in 
the unaffected father.  
Coding DNA variants were filtered to identify those predicted to have a moderate or high 
functional effect on the expressed protein, by VEP. The variants were filtered in two 
additional steps to identify the candidate variants of most interest: 
1. To exclude common variants that are less likely to be pathogenic, the variants were 
sorted by the minor allele frequency recorded for European populations (7). This step 
was to exclude those variants with a frequency > 0.0119.  
2. The final filtering step excluded any remaining missense variants that were not 
predicted to have a damaging or deleterious potential by either the SIFT or Polyphen 
software tools (8, 9). These tools use different algorithms to predict the effect of 
amino acid changes on protein function. 
 
Results 
 
Two of the variants identified are predicted to have a high functional impact with the Ensembl 
VEP software. These are summarised in table 1. They are both rare, loss-of-function variants. 
A premature stop codon was identified in EGFL8 and a frameshift mutation was identified in 
BTNL9. 
Any variants predicted to have a moderate functional effect are listed in table 2. These are 
non-synonymous (amino acid changing) missense mutations.   
 The SIFT and Polyphen scores are shown in Table 2, alongside their qualitative prediction. 
Both tools use a range of zero to one, but with opposite meanings. A SIFT score of 1.0 is 
predicted to be benign, whereas a Polyphen score of 1.0 is predicted to be damaging. 
 
Discussion and Conclusion 
 
New Findings and Previous Studies 
In a recent systematic review, we proposed that the pattern of cholesteatoma observed in 
this and some other families is typical of a monogenic or oligogenic disorder with incomplete 
penetrance. The mutations described in Table 1 are candidate variants of most interest, from 
this WES study, because they are predicted to be functionally important, high impact 
mutations. However, neither variant is rare enough to be presented as an exclusive 
underlying cause of cholesteatoma. As with most disease traits, we can predict that any 
genetic architecture (which is the number and effect size of any contributing variants) will be 
complex for cholesteatoma. 
EGFL8 and BTNL9 
EGFL8 is a highly conserved gene that encodes the EGF like domain multiple 8 protein, which 
is highly expressed in the skin (10). Interestingly, the stop-gain variant in EGFL8, rs141826798, 
has recently been reported to be significantly associated with psoriasis in UK Biobank 
participants (11). For both psoriasis and cholesteatoma, there is altered keratinocyte 
proliferation and differentiation. It is possible that EGFL8 variants have pleiotropic effects 
and/or that there is a common biological driver for these pathologies.  
BTNL9 encodes the butyrophilin like 9 protein.  Butyrophilins and butyrophilin-like proteins 
are part of the immunoglobulin superfamily, and have roles in adaptive and innate immunity 
(12).  There are no published disease-associations for the BTNL9 variant, rs367635312, to our 
knowledge.  
Missense variants 
We present the rare variants in table 2 because missense variants can also contribute to the 
pathophysiology of complex diseases.  
All deleterious rare variants that co-segregate with the disease phenotype will be interest to 
researchers investigating familial cholesteatoma.  
Implications for Research and Clinical Practice 
These are interesting preliminary findings from the first WES study of cholesteatoma to date. 
Further study will be required to determine whether EGFL8 or BTNL9 variants, or indeed the 
missense variants, are of any significance to cholesteatoma pathology. We also recognise that 
our analysis for deleterious variants was not exhaustive for this study because other 
mutation-effect prediction algorithms could be included in our variant filtering protocol. 
Additional families will now be analysed as part of the GOC study to identify and document 
other co-segregating variants with a putative functional impact. For families with similar 
vertical inheritance patterns, we will focus on a dominant model of inheritance, considering 
haploinsufficiency and gain of function variants. We acknowledge that this approach can only 
identify those variants with major or moderate effects on the disease phenotypes. 
If we identify recurrent candidate genes and gene pathways through WES studies of multiply-
affected families, this could increase our understanding of the cause and pathophysiology of 
cholesteatoma. 
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